Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy

JAMA Neurology

Volumn 72, Issue 6, 2015, Pages 666-675

  Ripolone, Michela ^a   Ronchi, Dario ^a   Violano, Raffaella ^a   Vallejo, Dionis ^b   Fagiolari, Gigliola ^a   Barca, Emanuele ^c   Lucchini, Valeria ^a   Colombo, Irene ^a   Villa, Luisa ^a   Berardinelli, Angela ^d   Balottin, Umberto ^d   Morandi, Lucia ^e   Mora, Marina ^e   Bordoni, Andreina ^a   Fortunato, Francesco ^a   Corti, Stefania ^a   Parisi, Daniela ^f   Toscano, Antonio ^f   Sciacco, Monica ^a   Di Mauro, Salvatore ^c   Comi, Giacomo P ^a   Moggio, Maurizio ^a   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c Department of Medicine   (United States)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e HS Raffaele   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 4; CYTOCHROME C OXIDASE; CYTRATE SYNTHASE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MYOBLAST DETERMINATION 1; MYOGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PORIN; PROSTAGLANDIN SYNTHASE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE COMPLEX SUBUNIT A; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; BIOGENESIS; CELL ASSAY; CELL FUNCTION; CELL LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INFANT; MALE; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MUSCLE BIOPSY; MUSCLE DEVELOPMENT; MUSCLE MITOCHONDRION; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESIDUE ANALYSIS; RESPIRATORY CHAIN; SPINAL MUSCULAR ATROPHY; SYNDROME DELINEATION; WESTERN BLOTTING; ADOLESCENT; METABOLISM; MITOCHONDRION; PHYSIOLOGY; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE;

ADOLESCENT; CHILD, PRESCHOOL; DNA, MITOCHONDRIAL; FEMALE; HUMANS; INFANT; MALE; MITOCHONDRIA; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; QUADRICEPS MUSCLE;

EID: 84931026162     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0178     Document Type: Article

References (63)

1. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120-2133.
2. Sossi V, Giuli A, Vitali T, et al. Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. Eur J Hum Genet. 2001;9(2):113-120.
3. Engel AG, Armstrong-Franzini C. Myology. 2nd ed. New York, NY: McGraw-Hill; 1994.
4. Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990;344(6266):540-541.
5. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165.
6. Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205-1214.
7. Terns MP, Terns RM. Macromolecular complexes: SMN-the master assembler. Curr Biol. 2001;11(21):R862-R864.
8. Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell. 1997;90(6):1023-1029.
9. Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell. 1997;90(6):1013-1021.
10. Meister G, Hannus S, Plöttner O, et al. SMNrp is an essential pre-mRNA splicing factor required for the formation of the mature spliceosome. EMBO J. 2001;20(9):2304-2314.
11. Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science. 2002;298(5599):1775-1779.
12. Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH. Differential SMN2 expression associated with SMA severity. Nat Genet. 1998;20(3):230-231.
13. Burlet P, Huber C, Bertrandy S, et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet. 1998;7(12):1927-1933.
14. Ito Y, Shibata N, Saito K, Kobayashi M, Osawa M. New insights into the pathogenesis of spinal muscular atrophy. Brain Dev. 2011;33(4):321-331.
15. Martínez-Hernández R, Soler-Botija C, Also E, et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol. 2009;68(5):474-481.
16. Hausmanowa-Petrusewicz I, Vrbová G. Spinal muscular atrophy: a delayed development hypothesis. Neuroreport. 2005;16(7):657-661.
17. Lee YI, Mikesh M, Smith I, Rimer M, Thompson W. Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol. 2011;356(2):432-444.
18. Martínez-Hernández R, Bernal S, Alias L, Tizzano EF. Abnormalities in early markers of muscle involvement support a delay inmyogenesis in spinal muscular atrophy. J Neuropathol Exp Neurol. 2014;73(6):559-567.
19. Berger A, Mayr JA, Meierhofer D, et al. Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol. 2003;105(3):245-251.
20. Acsadi G, Lee I, Li X, et al. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J Neurosci Res. 2009;87(12):2748-2756.
21. 2 mutation (G1521A) presenting as a spinal muscular atrophy type I phenotype. Am J Med Genet A. 2004;125 A(3):310-314.
22. Pronicki M, Kowalski P, Piekutowska-Abramczuk D, et al. A homozygous mutation in the SCO2 gene causes a spinal muscular atrophy like presentation with stridor and respiratory insufficiency. Eur J Paediatr Neurol. 2010;14(3):253-260.
23. Salviati L, Sacconi S, Rasalan MM, et al. Cytochrome-c oxidase deficiency due to a novel SCO2 mutationmimicsWerdnig-Hoffmann disease. Arch Neurol. 2002;59(5):862-865.
24. Mancuso M, Salviati L, Sacconi S, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene withmyopathy and SMA. Neurology. 2002;59(8):1197-1202.
25. Gotz A, Isohanni P, Pihko H, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain. 2008;131(pt 11):2841-2850.
26. Akman HO, Dorado B, Lopez LC, et al. Thymidine kinase 2 (H126N) knockinmice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet. 2008;17(16):2433-2440.
27. Bartesaghi S, Betts-Henderson J, Cain K, et al. Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. Hum Mol Genet. 2010;19(9):1669-1677.
28. Sciacco M, Fagiolari G, Lamperti C, et al. Lack of apoptosis inmitochondrial encephalomyopathies. Neurology. 2001;56(8):1070-1074.
29. Burglen L, Lefebvre S, Clermont O, et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics. 1996;32(3):479-482.
30. Bresolin N, Moggio M, Bet L, et al. Progressive cytochrome C oxidase deficiency in a case of Kearns-Sayre syndrome: morphological, immunological, and biochemical studies in muscle biopsies and autopsy tissues. Ann Neurol. 1987;21(6):564-572.
31. Gomez-Curet I, Robinson KG, Funanage VL, Crawford TO, Scavina M, Wang W. Robust quantification of the SMN gene copy number by real-time TaqMan PCR. Neurogenetics. 2007;8(4):271-278.
32. Galbiati S, Bordoni A, Papadimitriou D, et al. New mutations in TK2 gene associated with mitochondrial DNA depletion. Pediatr Neurol. 2006;34(3):177-185.
33. Spinazzola A, Viscomi C, Fernandez-Vizarra E, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38(5):570-575.
34. Boyer JG, Deguise MO, Murray LM, et al. Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Hum Mol Genet. 2014;23(16):4249-4259.
35. Bricceno KV, Martinez T, Leikina E, et al. Survival motor neuron protein deficiency impairs myotube formation by alteringmyogenic gene expression and focal adhesion dynamics. Hum Mol Genet. 2014;23(18):4745-4757.
36. Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One. 2007;2(9):e921. doi:10.1371/journal.pone.0000921.
37. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol. 2002;14(3):305-312.
38. Gabanella F, Carissimi C, Usiello A, Pellizzoni L. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum Mol Genet. 2005;14(23):3629-3642.
39. La Bella V, Cisterni C, Salaun D, Pettmann B. Survival motor neuron (SMN) protein in rat is expressed as different molecular forms and is developmentally regulated. Eur J Neurosci. 1998;10(9):2913-2923.
40. Germain-Desprez D, Brun T, Rochette C, Semionov A, Rouget R, Simard LR. The SMN genes are subject to transcriptional regulation during cellular differentiation. Gene. 2001;279(2):109-117.
41. Guettier-Sigrist S, Hugel B, Coupin G, Freyssinet JM, Poindron P, Warter JM. Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy. Muscle Nerve. 2002;25(5):700-708.
42. Hayhurst M, Wagner AK, Cerletti M, Wagers AJ, Rubin LL. A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein. Dev Biol. 2012;368(2):323-334.
43. Remels AH, Langen RC, Schrauwen P, Schaart G, Schols AM, Gosker HR. Regulation of mitochondrial biogenesis duringmyogenesis. Mol Cell Endocrinol. 2010;315(1-2):113-120.
44. Duguez S, Feasson L, Denis C, Freyssenet D. Mitochondrial biogenesis during skeletal muscle regeneration. Am J Physiol Endocrinol Metab. 2002;282(4):802-809.
45. Leary SC, Battersby BJ, Hansford RG, Moyes CD. Interactions between bioenergetics and mitochondrial biogenesis. Biochim Biophys Acta. 1998;1365(3):522-530.
46. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol. 2005;25(4):1354-1366.
47. Baldelli S, Aquilano K, Ciriolo MR. PGC-1α buffers ROS-mediated removal of mitochondria duringmyogenesis. Cell Death Dis. 2014;5:e1515. doi:10.1038/cddis.2014.458.
48. Campbell GR, Reeve A, Ziabreva I, et al. Mitochondrial DNA deletions and depletion within paraspinal muscles. Neuropathol Appl Neurobiol. 2013;39(4):377-389.
49. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3(2):49-51.
50. Simonds AK. Respiratory complications of the muscular dystrophies. Semin Respir Crit Care Med. 2002;23(3):231-238.
51. Di Meo I, Fagiolari G, Prelle A, Viscomi C, Zeviani M, Tiranti V. Chronic exposure to sulfide causes accelerated degradation of cytochrome C oxidase in ethylmalonic encephalopathy. Antioxid Redox Signal. 2011;15(2):353-362.
52. Zeviani M, Nonaka I, Bonilla E, et al. Fatal infantile mitochondrialmyopathy and renal dysfunction caused by cytochrome C oxidase deficiency: immunological studies in a new patient. Ann Neurol. 1985;17(4):414-417.
53. Muller-Hocker J, Droste M, Kadenbach B, Pongratz D, Hubner G. Fatalmitochondrial myopathy with cytochrome-c-oxidase deficiency and subunit-restricted reduction of enzyme protein in two siblings: an autopsy-immunocytochemical study. Hum Pathol. 1989;20(7):666-672.
54. Oldfors A, Sommerland H, Holme E, Tulinius M, Kristiansson B. Cytochrome c oxidase deficiency in infancy. Acta Neuropathol. 1989;77(3):267-275.
55. Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci. 2009;29(3):842-851.
56. Wadman RI, Vrancken AF, Van Den Berg LH, Van Der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. 2012;79(20):2050-2055.
57. J Montes, CE Garber, SS Kramer, et al. A randomized, controlled clinical trial of exercise in patients with spinal muscular atrophy: methods and baseline characteristics. J Neuromusc Dis. 2014;1(2):151-161.
58. Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab. 2011;14(1):80-90.
59. Srivastava S, Barrett JN, Moraes CT. PGC-1α/β upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations. Hum Mol Genet. 2007;16(8):993-1005.
60. Zheng B, Liao Z, Locascio JJ, et al; Global PD Gene Expression (GPEX) Consortium. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010;2(52):52ra73.
61. Tsunemi T, Ashe TD, Morrison BE, et al. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med. 2012;4(142):142ra97.
62. Da Cruz S, Parone PA, Lopes VS, et al. Elevated PGC-1α activity sustainsmitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 2012;15(5):778-786.
63. Montesano A, Luzi L, Senesi P, Mazzocchi N, Terruzzi I. Resveratrol promotesmyogenesis and hypertrophy in murinemyoblasts. J Transl Med. 2013;11:310. doi:10.1186/1479-5876-11-310.